Philips launched its intuitive intervention guidance platform, IntraSight Plus, which has been approved for clinical use in the US and Europe following CE marking and FDA 510(k) approval. The updated platform combines the most comprehensive diagnostic and treatment planning tools to provide efficiency, simplicity, and precision in one intuitive system. By streamlining access to key intervention tools, IntraSight Plus enables clinicians to diagnose, virtually plan treatments, guide device placement, and verify results.
All of this can be done on a single screen, supporting confident decision-making and better patient care. IntraSight Plus is now available on the US and European markets and helps improve workflow efficiency, which can reduce system operating time by up to 47%. Interventional cardiologists have traditionally relied exclusively on angiography for percutaneous coronary interventions (PCI).
Although guidelines support the use of intravascular ultrasound (IVUS) and physiological measurements in PCI, the systems and inputs for these are often separate. This makes implementation more challenging and less efficient in busy catheterization rooms (cath labs). IntraSight Plus addresses these challenges by bringing everything together in a single intuitive system.
This can lead to a 47% saving in system operating time and enables full control from the operating table. On Thursday, March 19, 2026, Prof. Dr. Jan-Malte Sinning performed the first treatment on a patient using IntraSight Plus at the Cellitinnen-Krankenhaus St. Vinzenz in Cologne, Germany.
The hospital recently upgraded the infrastructure of its catheterization laboratory with Philips Azurion intervention suites. The addition of IntraSight Plus to this ecosystem ensures an improved workflow for physicians. The patient in this treatment had an acute ST-elevation myocardial infarction (STEMI) in the left anterior descending artery (LAD) two days earlier and suffered from underlying complex three-vessel disease.
Using the Philips Azurion intervention platform in combination with the new IntraSight Plus system, Prof. Sinning performed a complete revascularization prior to discharge. Thanks to the integrated recording of angiography, physiological measurements, and intravascular imaging, a streamlined and intuitive workflow was created. This allowed treatment to be targeted at hemodynamically relevant lesions and ensured optimal stent placement, leading to better patient outcomes.
IntraSight Plus is a completely redesigned system that combines Philips' IntraSight and SyncVision technologies. It combines Class IA IVUS and direct measurement of wave-free ratio/fractional flow reserve (iFR/FFR), co-registration, tri-registration, and real-time visualization of medical devices in a single system. It makes the following possible: Precision PCI: Class IA IVUS and iFR data are displayed on a single screen, allowing physicians to view plaque morphology and its ischemic effects at every point along the blood vessel.
This enables physicians to plan their PCI, estimate outcomes, determine stent size and placement, and perform precise PCIs for improved patient care. Efficiency: Enter patient data only once. Thanks to streamlined communication between IntraSight Plus and Azurion DataHandler, customers spend less time operating multiple systems. Customer Control: This intuitive platform offers procedural guidance and central control at the bedside, enabling full control over the procedure at the bedside without leaving the sterile field.
IntraSight Plus is built on a common Philips architecture and can also be linked to the Azurion platform and the company's PACS system for even better integration within a Philips laboratory environment. IntraSight Plus is approved in the US under the FDA 510(k) procedure and bears the CE mark in Europe. Commercial availability is subject to market introduction and applicable regulatory requirements.
